Co-evolution of Oncogenic KRAS Signaling and LILRBhigh Macrophages Drives Pancreatic Cancer Recurrence

This study identifies a co-evolved therapeutic vulnerability in recurrent pancreatic cancer where oncogenic KRAS signaling and LILRB4-expressing macrophages mutually reinforce tumor progression, suggesting that dual targeting of this axis offers a promising strategy to prevent recurrence.

The Gist

The Big Picture: Why Pancreatic Cancer Comes Back

Imagine pancreatic cancer (PDAC) as a very stubborn weed in a garden. Doctors can surgically remove the visible weed (the tumor), but often, tiny roots remain hidden in the soil. Within a few years, the weed grows back, usually stronger and harder to kill than before.

This study asks a crucial question: Why does the weed come back?

The researchers discovered that it's not just the weed growing on its own. It's a secret partnership between the weed and the soil itself. Specifically, the cancer cells team up with a specific type of "helper" cell in the body's immune system to rebuild and protect the tumor.

---

The Two Main Characters in the Story

1. The "Super-Weed" (The Cancer Cells)

Inside the cancer cells, there is a master switch called KRAS. Think of KRAS as the engine of a car.

• In the beginning: The engine is running, but maybe not at full speed.
• When it comes back: The cancer cells don't just grow back; they turbocharge the engine. They add more fuel to the KRAS switch, making it run at maximum power. This turns the cancer cells into a "Basal-like" state—a super-aggressive, shape-shifting form that is very good at hiding and spreading.

2. The "Bodyguard" (The Macrophages)

Your body has an immune system with many soldiers. One type of soldier is called a Macrophage. Usually, they are the "good guys" that eat up bacteria and cancer.

• The Twist: The cancer cells trick a specific group of these soldiers. They turn them into LILRB4+ Macrophages.
• The Metaphor: Imagine the cancer cells hiring a corrupt bodyguard. Instead of protecting the garden, this bodyguard (the LILRB4+ macrophage) stands guard at the gate, blocking the good immune cells from entering and handing the cancer cells a shield.

---

The Secret Handshake: How They Work Together

The study found that these two characters have a co-evolutionary dance. They didn't just happen to be near each other; they evolved together to ensure the cancer survives.

1. The Signal: The turbocharged cancer cells (with high KRAS) send out a signal.
2. The Response: The corrupt bodyguards (LILRB4+ macrophages) hear the signal and move right next to the cancer cells.
3. The Deal:
   • The bodyguards protect the cancer cells from the rest of the immune system.
   • In exchange, the cancer cells give the bodyguards signals that make them even more aggressive and helpful to the tumor.
   • Together, they create a safe zone (a niche) where the cancer can hide, change its shape, and grow back stronger.

Analogy: Think of the cancer cell as a criminal and the LILRB4 macrophage as a corrupt police officer. The criminal bribes the officer. The officer then stands outside the criminal's house, telling other police (the immune system), "Nothing to see here, move along," while secretly handing the criminal a map to escape routes.

---

The Breakthrough: How to Stop the Cycle

The researchers didn't just find the problem; they found a way to break the partnership. They tested a new strategy involving two weapons:

1. Weapon A: Turn off the Engine. They used a drug to slow down the KRAS engine in the cancer cells.

   • Result: This slowed the cancer down, but the corrupt bodyguards (macrophages) were still there, protecting the remaining cancer. The cancer eventually found a way to keep going.

2. Weapon B: Fire the Bodyguard. They developed a new antibody (a "first-in-class" drug) that specifically targets the LILRB4 receptor on the macrophages.

   • Result: This effectively "fired" the corrupt bodyguard. The immune system could finally see the cancer again.

3. The Winning Strategy: The One-Two Punch.

   • When they used both weapons together, the results were amazing.
   • By turning off the engine and firing the bodyguard at the same time, the cancer had no protection and no power. The tumor shrank significantly more than with either treatment alone.

Why This Matters

• For Patients: This explains why pancreatic cancer is so hard to treat after surgery. It's not just about killing the tumor cells; it's about breaking the alliance between the tumor and its immune system helpers.
• For the Future: This study suggests that the best way to stop pancreatic cancer from coming back is to use a combination therapy: one drug to hit the cancer's engine (KRAS) and another to remove its immune system bodyguards (LILRB4).

Summary in One Sentence

Pancreatic cancer comes back because the tumor cells turbocharge their own growth engine and hire corrupt immune "bodyguards" to protect them; the cure lies in firing those bodyguards while simultaneously turning off the engine.

Technical Summary

1. Problem Statement

Pancreatic Ductal Adenocarcinoma (PDAC) has an extremely poor prognosis, with recurrence occurring in up to 80% of patients within five years despite surgical resection. While genomic studies have established KRAS mutations as central drivers, the biological mechanisms sustaining postoperative relapse remain unclear. Specifically, there is a lack of understanding regarding:

• How tumor-intrinsic signaling (specifically KRAS allele dosage) evolves during recurrence.
• How the tumor microenvironment (TME), particularly the immune landscape, remodels in the context of residual disease.
• The dynamic, spatiotemporal co-evolution of tumor cells and immune cells that drives the aggressive phenotype of recurrent PDAC.

2. Methodology

The study employed a comprehensive, multi-layered approach combining large-scale clinical data, longitudinal multi-omics profiling, and functional validation:

• Clinical Cohorts:
  • Survival Analysis: A cohort of 2,710 PDAC patients to establish recurrence as a primary determinant of mortality.
  • Discovery Cohort: 18 matched pairs of primary and locally recurrent PDAC tumors from the same patients (same anatomical site), collected before and after recurrence.
  • Validation Cohorts: An independent multiplex immunofluorescence (mIF) cohort (n=190) and public datasets (TCGA, HTAN-WUSTL, GSE202051).
• Multi-Omics Profiling (Discovery Cohort):
  • Whole-Exome Sequencing (WES): To assess somatic mutations and KRAS mutant allele dosage.
  • Bulk RNA Sequencing: To quantify lineage states (Classical vs. Basal-like) and pathway enrichment.
  • Single-Nucleus RNA Sequencing (snRNA-seq): To resolve cellular heterogeneity at single-cell resolution (71k primary cells, 82k recurrent cells).
  • Multiplex Spatial Imaging (mIF): To validate spatial co-localization of cell types in tissue sections.
• Computational Analysis:
  • Integration of datasets using Harmony for batch correction.
  • Cell-type annotation, trajectory inference (CytoTRACE2, scVelo), and ligand-receptor interaction analysis (LIANA, CellChat, NicheNet).
  • Deconvolution of spatial transcriptomics data using cell2location.
• Functional Validation:
  • In Vitro: Patient-Derived Organoid (PDO) – Macrophage co-culture systems; Transwell invasion assays; siRNA knockdown of LILRB4.
  • In Vivo:
    • Immunocompetent KPC (KRAS/p53/Smad4) Genetically Engineered Mouse Models (GEMM) with acquired resistance.
    • Subcutaneous xenograft models co-injecting PANC-1 cells with macrophages.
  • Therapeutic Intervention: Testing a first-in-class human anti-LILRB4 monoclonal antibody (hu36B10D1) alone and in combination with a KRAS G12D inhibitor (HRS-4642).

3. Key Contributions

• Longitudinal Framework: The study provides a rare, direct comparison of matched primary and recurrent tumors from the same patient, minimizing inter-patient variability and isolating temporal evolution.
• Discovery of a Co-Evolutionary Axis: It identifies a specific feedback loop where amplified KRAS signaling in tumor cells drives the expansion of a specific immunosuppressive macrophage subset (LILRB4+), which in turn reinforces tumor plasticity and resistance.
• Therapeutic Target Identification: It validates LILRB4 as a critical, actionable target in the TME and demonstrates that dual targeting of the tumor (KRAS) and the microenvironment (LILRB4) is superior to monotherapy.

4. Key Results

A. Enhanced KRAS Signaling and Basal Reprogramming

• KRAS Dosage: Recurrent tumors exhibited a significant increase in KRAS mutant allele frequency (VAF) and mutant allele dosage compared to matched primaries. High KRAS dosage correlated with poor survival in TCGA data.
• Transcriptional Shift: Recurrent tumors showed a shift from "Classical" to "Basal-like" transcriptional states. This was characterized by the expansion of a Basal_KRAShigh malignant cell state, which displayed high KRAS copy-number amplification, elevated EMT (Epithelial-Mesenchymal Transition) scores, and increased plasticity.
• Trajectory: Pseudotime analysis confirmed a trajectory from Classical $\to$ Basal_KRASlow $\to$ Basal_KRAShigh states during recurrence.

B. Expansion of LILRBhigh Macrophages

• Macrophage Heterogeneity: Single-cell analysis identified a distinct macrophage subset (LILRBhigh) characterized by high expression of LILRB1–5 and pro-tumor markers (CD163, MRC1).
• Recurrence Association: This subset was significantly enriched in recurrent tumors compared to primaries and displayed the highest immunosuppressive signature scores.
• Spatial Co-localization: Spatial transcriptomics and mIF confirmed that Basal_KRAShigh tumor cells and LILRBhigh macrophages preferentially co-localize, a feature significantly enhanced in recurrent lesions.
• Specificity of LILRB4: Among the family, LILRB4 was the specific driver upregulated in recurrence. High density of LILRB4+ macrophages correlated with worse relapse-free and overall survival.

C. Functional Mechanism: The KRAS–LILRB4 Axis

• Bidirectional Crosstalk: Ligand-receptor analysis revealed that Basal_KRAShigh cells secrete ligands (e.g., FN1, MDK, TGFBI) that engage receptors (e.g., LILRB1/2, Integrins) on LILRBhigh macrophages. This interaction activates TNF$\alpha$, EMT, and KRAS–ERK signaling in both cell types.
• Macrophage-Driven Plasticity: Co-culture experiments showed that LILRB4+ macrophages induce basal-like reprogramming, increase ERK/MEK phosphorylation, and enhance invasiveness in PDAC cell lines and organoids. Knockdown of LILRB4 in macrophages attenuated these effects.
• Resistance Mechanism: In mouse models, KRAS inhibition (HRS-4642) successfully reduced Basal_KRAShigh tumor cells but failed to deplete LILRB4+ macrophages, suggesting the macrophage niche supports residual disease and resistance.

D. Therapeutic Efficacy of Dual Targeting

• Monotherapy Limits: Anti-LILRB4 antibody (hu36B10D1) alone had minimal effect on tumors without macrophages but suppressed growth in macrophage-containing models. KRAS inhibition alone was attenuated by the presence of macrophages.
• Synergy: The combination of KRAS inhibitor (HRS-4642) + Anti-LILRB4 mAb achieved superior tumor control in macrophage-containing xenografts and KPC models, outperforming either monotherapy. This suggests that dismantling the tumor-myeloid axis restores sensitivity to oncogenic pathway inhibition.

5. Significance

• Mechanistic Insight: The study redefines PDAC recurrence not merely as a tumor-intrinsic evolutionary event but as a co-evolved ecosystem where oncogenic signaling and immune remodeling mutually reinforce each other.
• Clinical Implication: It challenges the current paradigm of treating recurrence based solely on primary tumor genetics. It suggests that the TME, specifically LILRB4+ macrophages, is a critical driver of relapse.
• Therapeutic Strategy: The findings propose a novel combinatorial strategy: dual targeting of KRAS signaling and LILRB4. This approach aims to simultaneously suppress tumor plasticity and disrupt the immunosuppressive niche, potentially preventing or delaying recurrence in PDAC.
• Translational Potential: The development and validation of a first-in-class human anti-LILRB4 antibody provide a tangible therapeutic candidate for immediate preclinical and future clinical investigation in combination with KRAS-targeted therapies.